ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024Business Wire • 04/24/24
ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers MarketBusiness Wire • 04/23/24
ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency ProgramBusiness Wire • 03/26/24
ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024Business Wire • 02/21/24
ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow on Monday, February 12, 2024Business Wire • 02/05/24
ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®Business Wire • 12/20/23
Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+PRNewsWire • 12/12/23
A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)Business Wire • 11/30/23
Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) PatientsBusiness Wire • 11/15/23
ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow on Tuesday, November 14, 2023Business Wire • 11/09/23
ChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers NationwideBusiness Wire • 11/01/23
ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023Business Wire • 10/31/23
ChromaDex and Zesty Paws® Crack the Code on Cellular Health for Dogs With ‘Healthy Aging' LineBusiness Wire • 10/26/23
A Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis PatientsBusiness Wire • 10/02/23
Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NMNBusiness Wire • 08/24/23
ChromaDex Launches Tru Niagen® with iHerb, the World's Number One Online Destination for Health and WellnessBusiness Wire • 08/08/23